GlassScriptPhysician profile
Aubrey Kenneth Harper
NPI 1134143456
$2,830.70
in general payments reported to CMS, 2019-2025
33 companies · $547 in 2025
The $547 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $223 · 2021: $437 · 2022: $378 · 2023: $548 · 2024: $396 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,393 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.81 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.20 | 2019-2025 | |
| Astellas Pharma US INC | $497.14 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $399.26 | 2021-2025 | |
| Exeltis, USA INC. | $174.80 | 2021-2025 | Slynd |
| Sumitomo Pharma America, INC. | $105.87 | 2023-2025 | Gemtesa, Myfembree |
| Biogen, INC. | $95.54 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $87.90 | 2019-2020 | |
| Allergan, INC. | $85.89 | 2019-2020 | |
| Baxter Healthcare | $80.22 | 2022-2024 | Floseal |
| Avion Pharmaceuticals | $65.34 | 2019-2022 | |
| Aspira Women'S Health INC | $58.97 | 2023 | Ova1 |
| Mylan Pharmaceuticals INC. | $41.99 | 2020-2022 | |
| Medtronic, INC. | $41.70 | 2024 | Interstim |
| Pfizer INC. | $36.85 | 2024-2025 | |
| Duchesnay USA Incorporated | $35.92 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $32.63 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $32.21 | 2024 | |
| Myovant Sciences INC. | $29.09 | 2021-2022 | |
| Roche Diagnostics Corporation | $28.81 | 2019 | |
| Currax Pharmaceuticals LLC | $27.83 | 2020-2021 | |
| Evofem Biosciences, INC. | $26.75 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $24.91 | 2023 | |
| Organon LLC | $19.83 | 2025 | Nexplanon |
| Scynexis, INC. | $19.46 | 2022 | |
| Agile Therapeutics, INC. | $19.05 | 2021 | |
| Coopersurgical, INC. | $18.86 | 2019 | |
| Medline Industries LP | $17.21 | 2024 | |
| Alexion Pharmaceuticals, INC. | $16.80 | 2022 | |
| Optumhealth Care Solutions, LLC | $16.74 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Therapeuticsmd, INC. | $16.21 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.14 | 2019 | |
| Millicent US INC | $13.60 | 2025 | Femlyv, Intrarosa |
| Novo Nordisk INC | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aubrey Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.